Evommune, Inc. EVMN

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $13.00M · Filed Mar 5, 2026

Evommune, Inc. (EVMN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $13.0 million and a net loss of $68.9 million. Free cash flow was -$76.7 million. As of Jun 30, 2026 it held $288.0 million in cash and investments and $8.6 million in total debt.

Revenue
$13.00M
Net income
$-68.87M
Operating cash flow
$-76.44M
Free cash flow
$-76.68M
EPS
$-11.22
Dividend per share
None
Shares outstanding
36.02M
Net cash
$279.38M
as of Jun 30, 2026
Operating margin
-623.6%
FY 2025

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EVMN (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
2044725

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$13.0M
Operating income
-$81.1M
Net income
-$68.9M
Diluted EPS
-$11.22
Operating cash flow
-$76.4M
Free cash flow
-$76.7M
Total assets
$224.9M
Total liabilities
$19.4M
Stockholders' equity
$205.6M
Cash and investments
$216.7M
Total debt
$2.1M

Recent SEC filings

Form Description Filed Period
8-K Current report
Regulation FD disclosure
 Nov 5, 2026 Nov 5, 2026
8-K Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
 Nov 4, 2026 Nov 4, 2026
8-K Current report
Regulation FD disclosure
 Oct 1, 2026 Oct 1, 2026
8-K Current report
Regulation FD disclosure
 Sep 23, 2026 Sep 23, 2026
8-K Current report
Regulation FD disclosure
 Sep 15, 2026 Sep 15, 2026
8-K Current report
Regulation FD disclosure, Other events
 Sep 9, 2026 Sep 8, 2026

All 138 Evommune, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.